Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells

Mitra Torabi ^1,2 , Ayuob Aghanejad ¹ * , Pouria Savadi ³ , Abolfazl Barzegari ¹, Yadollah Omidi ⁴ , Jaleh Barar ⁴ *

Cited by CrossRef: 1

1- Dehghan S, Naghipour A, Anbaji F, Golshanrad P, Mirazi H, Adelnia H, Bodaghi M, Far B. Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoniosomes with controlled release and improved uptake. International Journal of Pharmaceutics. 2023;640:122977 [Crossref]

2- Estirado S, Díaz-García D, Fernández-Delgado E, Viñuelas-Zahínos E, Gómez-Ruiz S, Prashar S, Rodríguez A, Luna-Giles F, Pariente J, Espino J. Melatonin Derivative-Conjugated Formulations of Pd(II) and Pt(II) Thiazoline Complexes on Mesoporous Silica to Enhance Cytotoxicity and Apoptosis against HeLa Cells. Pharmaceutics. 2024;16(1):92 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons